Cargando…

A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study

PURPOSE: Clonidine may help prevent cardiac complications in patients undergoing non-cardiac surgery and receiving chronic beta-blocker therapy. We conducted a multicentre pilot randomized trial to estimate recruitment rates for a full-scale trial and to assess the safety and tolerability of combini...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijeysundera, Duminda N., Choi, Peter T., Badner, Neal H., Brasher, Penelope M., Dresser, George K., Delgado, Diego H., Beattie, W. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194011/
https://www.ncbi.nlm.nih.gov/pubmed/25189430
http://dx.doi.org/10.1007/s12630-014-0226-6
_version_ 1782339070678007808
author Wijeysundera, Duminda N.
Choi, Peter T.
Badner, Neal H.
Brasher, Penelope M.
Dresser, George K.
Delgado, Diego H.
Beattie, W. Scott
author_facet Wijeysundera, Duminda N.
Choi, Peter T.
Badner, Neal H.
Brasher, Penelope M.
Dresser, George K.
Delgado, Diego H.
Beattie, W. Scott
author_sort Wijeysundera, Duminda N.
collection PubMed
description PURPOSE: Clonidine may help prevent cardiac complications in patients undergoing non-cardiac surgery and receiving chronic beta-blocker therapy. We conducted a multicentre pilot randomized trial to estimate recruitment rates for a full-scale trial and to assess the safety and tolerability of combining clonidine with chronic beta-blockade. METHODS: Patients who were at elevated perioperative cardiac risk, receiving chronic beta-blockade, and scheduled for major non-cardiac surgery were recruited in a blinded (participants, clinicians, outcome assessors) placebo-controlled randomized trial at three Canadian hospitals. Participants were randomized to clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(−1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge, whichever came first) or matching placebo. Feasibility was evaluated based on recruitment rates, with each centre being required to recruit 50 participants within 12-18 months. Additionally, we reviewed study drug withdrawals and safety outcomes, including clinically significant hypotension or bradycardia. RESULTS: Eighty-two of the 168 participants were randomized to receive clonidine and 86 to receive placebo. The average time to recruit 50 participants at each centre was 14.3 months. Six patients (7%) withdrew from clonidine, while four (5%) withdrew from placebo. Based on qualitative review, there were no major safety concerns related to clonidine. There was a moderate overall rate of cardiac morbidity, with 18 participants (11%) suffering postoperative myocardial infarction. CONCLUSION: This pilot randomized trial confirmed the feasibility, safety, and tolerability of a full-scale trial of oral and transdermal clonidine for reducing the risk of cardiac complications during non-cardiac surgery. This trial was registered at www.clinicaltrials.gov: NCT00335582. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12630-014-0226-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4194011
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-41940112014-10-15 A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study Wijeysundera, Duminda N. Choi, Peter T. Badner, Neal H. Brasher, Penelope M. Dresser, George K. Delgado, Diego H. Beattie, W. Scott Can J Anaesth Reports of Original Investigations PURPOSE: Clonidine may help prevent cardiac complications in patients undergoing non-cardiac surgery and receiving chronic beta-blocker therapy. We conducted a multicentre pilot randomized trial to estimate recruitment rates for a full-scale trial and to assess the safety and tolerability of combining clonidine with chronic beta-blockade. METHODS: Patients who were at elevated perioperative cardiac risk, receiving chronic beta-blockade, and scheduled for major non-cardiac surgery were recruited in a blinded (participants, clinicians, outcome assessors) placebo-controlled randomized trial at three Canadian hospitals. Participants were randomized to clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(−1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge, whichever came first) or matching placebo. Feasibility was evaluated based on recruitment rates, with each centre being required to recruit 50 participants within 12-18 months. Additionally, we reviewed study drug withdrawals and safety outcomes, including clinically significant hypotension or bradycardia. RESULTS: Eighty-two of the 168 participants were randomized to receive clonidine and 86 to receive placebo. The average time to recruit 50 participants at each centre was 14.3 months. Six patients (7%) withdrew from clonidine, while four (5%) withdrew from placebo. Based on qualitative review, there were no major safety concerns related to clonidine. There was a moderate overall rate of cardiac morbidity, with 18 participants (11%) suffering postoperative myocardial infarction. CONCLUSION: This pilot randomized trial confirmed the feasibility, safety, and tolerability of a full-scale trial of oral and transdermal clonidine for reducing the risk of cardiac complications during non-cardiac surgery. This trial was registered at www.clinicaltrials.gov: NCT00335582. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12630-014-0226-6) contains supplementary material, which is available to authorized users. Springer US 2014-09-05 2014 /pmc/articles/PMC4194011/ /pubmed/25189430 http://dx.doi.org/10.1007/s12630-014-0226-6 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Reports of Original Investigations
Wijeysundera, Duminda N.
Choi, Peter T.
Badner, Neal H.
Brasher, Penelope M.
Dresser, George K.
Delgado, Diego H.
Beattie, W. Scott
A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study
title A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study
title_full A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study
title_fullStr A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study
title_full_unstemmed A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study
title_short A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study
title_sort randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the epic study
topic Reports of Original Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194011/
https://www.ncbi.nlm.nih.gov/pubmed/25189430
http://dx.doi.org/10.1007/s12630-014-0226-6
work_keys_str_mv AT wijeysunderadumindan arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT choipetert arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT badnernealh arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT brasherpenelopem arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT dressergeorgek arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT delgadodiegoh arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT beattiewscott arandomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT wijeysunderadumindan randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT choipetert randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT badnernealh randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT brasherpenelopem randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT dressergeorgek randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT delgadodiegoh randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy
AT beattiewscott randomizedfeasibilitytrialofclonidinetoreduceperioperativecardiacriskinpatientsonchronicbetablockadetheepicstudy